At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 29 enrolled
Drug / intervention
AEGR-733drug
Likely dose
AEGR-733 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy
In Brief
A Phase 3 clinical trial evaluating AEGR-733 for Homozygous Familial Hypercholesterolemia. Completed, enrolled 29 participants across 10 sites in 4 countries.
Detailed Summary
The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHomozygous Familial Hypercholesterolemia
CountriesCanada, Italy, South Africa, United States
CollaboratorsFDA Office of Orphan Products Development
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedAug 2008
Primary CompletionSep 2010
Study CompletionOct 2011
TodayJul 2026
First PostedAug 8, 2008
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2010
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.9 years ago
Interventions
AEGR-733drug
5-80 mg daily by mouth for 1.5 yrs